The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Beddingfield, Brandon J., Iwanaga, Naoki, Chapagain, Prem P., Zheng, Wenshu, Roy, Chad J., Hu, Tony Y., Kolls, Jay K., Bix, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Leading Edge Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566794/
https://www.ncbi.nlm.nih.gov/pubmed/33102950
http://dx.doi.org/10.1016/j.jacbts.2020.10.003
Descripción
Sumario:Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin−based mechanism and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/− ACE2) and the interaction between α5β1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.

Ejemplares similares